文献速递静脉血栓栓塞慢性静脉疾病

深静脉血栓与血栓后综合征静脉支架置入后的抗凝管理与复发性血栓形成

Anticoagulation Management and Recurrent Thrombosis after Venous Stenting for Deep Vein Thrombosis and Post-thrombotic Syndrome.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2026-01-29

本研究评估深静脉血栓(DVT)或血栓后综合征(PTS)患者静脉支架置入后的抗凝管理及复发性静脉血栓栓塞(VTE)。停用抗凝后复发的5例均重启抗凝并恢复支架通畅。

要点

  • 静脉支架术后复发性VTE发生率为38%,其中93%为支架内再血栓。
  • 87%的复发性VTE发生在持续抗凝治疗期间,提示抗凝可能不足以完全预防。
  • 停用抗凝后复发的5例重启抗凝后支架通畅性均恢复。

核心结论

  • 静脉支架置入后复发性VTE发生率为38%(DVT 32%,PTS 45%),几乎均为支架内再血栓。
  • 约四分之一患者停用抗凝后发生VTE,但重启抗凝后支架通畅性均恢复。
  • 未识别出复发性VTE的独立危险因素。

研究设计与样本

  • 所有患者均进行易栓症检测,主要终点为抗凝或抗血小板管理,次要终点为复发性VTE及潜在危险因素。

主要发现

  • 中位随访250周(IQR 158–439),57例(72%)继续抗凝,22例(28%)停止抗凝。
  • 30例(38%)发生复发性VTE,中位发生时间11周(IQR 3–129),其中93%为支架内再血栓。
  • 一期通畅率62%(49例),二期通畅率94%(74例)。
  • 87%的复发性VTE发生在抗凝治疗期间;停用抗凝后复发的5例均重启抗凝。

临床怎么用

  • 静脉支架术后需密切监测支架内再血栓,即使持续抗凝仍可能发生。
  • 停用抗凝后出现复发性VTE应重启抗凝,可能有助于恢复支架通畅。
  • 易栓症和左髂静脉压迫综合征对复发风险的影响需进一步验证,暂不能作为决策依据。

局限性

  • 回顾性设计,抗凝管理无标准化方案。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There are no evidence based recommendations for anticoagulation management after venous procedures. This study aimed to evaluate how anticoagulation was managed after venous stenting for deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS). METHODS: Patients who underwent venous stenting for DVT or PTS from May 2006 to November 2021 were screened for inclusion. The primary endpoint was post-interventional management of anticoagulation or antiplatelet therapy. Secondary endpoints were recurrent venous thromboembolism (VTE) and potential risk factors (e.g., thrombophilia and left iliac vein compression syndrome). All patients underwent thrombophilia tests for the study's purpose. Descriptive statistics were applied for anticoagulation management. Recurrent VTE free survival was estimated using Kaplan-Meier methods (log rank). Binary logistic regression was conducted to estimate risk factors for recurrent VTE. RESULTS: Seventy nine patients were included: 41 DVT and 38 PTS. Until the last follow up (median 250 weeks, interquartile range [IQR] 158, 439), anticoagulation was continued for 57 (72%) and stopped for 22 (28%) patients. Post-interventional recurrent VTE occurred in 30 (38%) patients (32% DVT [n = 13]; 45% PTS [n = 17]) after a median duration of 11 weeks (IQR 3, 129), of which 93% were in stent re-thrombosis. Primary patency was 62% (n = 49) and secondary patency 94% (n = 74). Most recurrent VTEs (87%) occurred during anticoagulant therapy. Anticoagulation was re-started in all five patients with recurrent VTE after cessation of anticoagulant therapy. Anticoagulant therapy remained stopped in the absence of recurrent VTE (n = 17). Thrombophilia seemed to be statistically significantly associated with increased recurrent VTE (odds ratio 3.02, 95% confidence interval 1.13 - 8.07; p = .027) and left iliac vein compression syndrome with decreased recurrent VTE (odds ratio 0.30, 95% confidence interval 0.10 - 0.90; p = .032). Significance was lost in multivariable analysis. CONCLUSION: Recurrent VTE occurred in 38% patients (32% DVT; 45% PTS), almost always (93%) in stent re-thrombosis. Although approximately a quarter of patients experienced VTE after cessation of anticoagulation, stent patency was restored in all cases. No risk factors for recurrent VTE were identified.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Bakas JM, Lauw MN, Kruip MJHA, et al. Anticoagulation Management and Recurrent Thrombosis after Venous Stenting for Deep Vein Thrombosis and Post-thrombotic Syndrome. Eur J Vasc Endovasc Surg. 2026. PMID: 41620160. doi:10.1016/j.ejvs.2026.01.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。